1007882-12-3

Basic information

• Product Name: (S)-2-[5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y
• Synonyms: (S)-2-[5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y;1-Pyrrolidinecarboxylic acid, 2-[5-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-iMidazol-2-yl]-, 1,1-diMethylethyl ester, (2S)-;2-{4-[4-(4,4,5,5-TetraMethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-iMidazol-2-yl}-pyrrolidine-1-carboxylic acid tert-butyl ester;(S)-tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate;(S)-2-[5-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-yl;tert-butyl (2S)-2-[5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2 -yl)phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylate;tert-butyl(S)-2-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate;(S)-tert-Butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)p
• CAS NO: 1007882-12-3
• Molecular Formula: C₂₄H₃₄BN₃O₄
• Molecular Weight: 439.37
• Mol File: 1007882-12-3.mol
• Article Data: 47

Chemical Properties

• Boiling Point: 618.0±55.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.07±0.10(Predicted)
• CAS DataBase Reference: (S)-2-[5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-[5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y(1007882-12-3)
• EPA Substance Registry System: (S)-2-[5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y(1007882-12-3)

Safety Data

• Hazardous Substances Data: 1007882-12-3(Hazardous Substances Data)

Usage

General Description

(S)-2-[5-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y is a chemical compound that contains boron and nitrogen atoms in its structure. It is a chiral molecule with a specific orientation of its atoms, denoted by the (S)- prefix. The compound also contains a phenyl group and an imidazole ring, which are important for its chemical and biological activities. (S)-2-[5-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y may have potential applications in materials science, medicinal chemistry, and organic synthesis due to its unique structure and properties. Further research and studies are needed to fully understand the potential uses and effects of this chemical compound.

Upstream product

• 1007882-04-3 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 73183-34-3 bis(pinacol)diborane 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 128120-93-4 (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester 
• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 
• 1007881-98-2 y 
• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 
• 147-85-3 L-proline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1007882-04-3 (S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1007882-23-6 methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate 
• 791-28-6 Triphenylphosphine oxide 
• 1007882-40-7 benzyl tert-butyl (2S,2'S)-2,2'-(4,4'-biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-pyrrolidinecarboxylate) 
• 1007883-48-8 (S)-2-[5-(2-{4-[2-((S)-1-tert-butoxycarbonyl-pyrrolidin-2-yl)-3H-imidazol-4-yl]-phenyl}-pyrimidin-5-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1085706-46-2 (S)-tert-butyl 2-(5-(4'-(2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-pyrazol-3-yl)pyrrolidine-1-carboxylate 
• 1181457-55-5 C₃₆H₃₉N₇O₃ 
• 1228214-99-0 (R)-3-(4-{4'-[2-((S)-1-tert-butoxycarbonyl-pyrrolidin-2-yl)-1H-imidazol-4-yl]-biphenyl-4-yl}-1H-imidazol-2-yl)-1,8-dioxa-4-aza-spiro[4.5]decane-4-carboxylic acid benzyl ester 
• 1250937-01-9 C₄₂H₄₈N₆O₄ 
• 1369392-15-3 tert-butyl (S)-2-(5-(4-hydroxyphenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1241378-08-4 C₄₀H₄₆N₆O₄ 
• 1240428-03-8 C₃₄H₄₂N₆O₄ 
• 1255936-27-6 C₃₀H₄₈BN₃O₅Si 
• 1256383-42-2 (S)-2-{5-[4-(4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2-yl)phenyl]imidazol-2-yl}pyrrolidine hydrochloride 
• 1240427-70-6 (S,S)-2-((4'-(2-(1-tert-butoxycarbonylpyrrolidin-2-yl)-3H-imidazol-4-yl)biphenyl-4-ylmethyl)carbamoyl)pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emitasvir

A new approach to the synthesis of Emitasvir (DAG181), a small molecule hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor, is described. Enantioselective enzymatic desymmetrization with hydrolases in the synthetical approach can significantly avoid the loss of chiral raw materials in the resolution process. The synthesis route is further optimized and scaled-up to establish a new process that is applied to the preparation of kilogram scales of target active pharmaceutical ingredients (APIs). Compared with our initial process, the overall yield of target API was dramatically improved from 17 to 40%.

DICARBAMATE INHIBITORS OF NS5A FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS AND RELATED DISEASES

Dicarbamate compounds as inhibitors of NS5A, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodmgs, and pharmaceutical compositions t

Monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and preparation method

The invention discloses a monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and a preparation method. The monoglycosyl-containing heterocyclic compound has a chemical structure represented by a formula I shown in the description. The monoglycosyl-containing heterocyclic compound disclosed by the invention can be used for effectively inhibiting protease of the hepatitis C viruses and treating infection of the hepatitis C viruses (HCV).